Peter Goadsby and his group are world-class experts in conducting translational research in headache, aimed at dissecting molecular and neurobiological mechanisms for migraine pain. In addition, they are among the top few worldwide in identifying and unravelling the mode of action of migraine treatments. For instance, they were pioneers in characterising the full potential for central neural effects of acute migraine treatments. Based on his research calcitonin gene-related peptide (CGRP) is in development as a new class of therapy. He also performed seminal work towards unravelling therapeutic effects of 5-HT1F receptor agonists (ditans), and recently on orexin receptor antagonists (rexants) and acidsensing ion channel blockers as potential migraine treatment targets.
Website KCL: Department of Basic and Clinical Neuroscience
- Participant in WP4.
Peter Goadsby, MD, PhD, is Professor of Neurology at King’s College London. He is clinical lead for headache at King’s College Hospital. Before moving to the King’s he was in San Francisco and prior to that he was for many years at UCL. His research experience includes basic science on trigeminovascular nociception, brain imaging in primary headache disorders, and clinical care of headache patients. He is the current President of the International Headache Society.
Philip Holland, PhD, is Lecturer in Neuroscience (Headache) at KCL and is an up and coming leader in basic migraine research.